February 2023—Agilent Technologies announced an agreement with Quest Diagnostics that will enable providers and patients in the United States to access the Agilent Resolution ctDx First liquid biopsy next-generation sequencing test.
Under the terms of the agreement, Quest will offer ctDx First to health care providers in the United States seeking a minimally invasive liquid biopsy test option as a companion diagnostic for Krazati. The test can be ordered electronically through the Quest connectivity platform.
The Resolution ctDx First is the first liquid biopsy test approved by the FDA as a companion diagnostic to identify patients with advanced non-small cell lung cancer who may benefit from treatment with Krazati. Krazati (adagrasib) received accelerated approval as a targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA-approved test, who have received at least one prior systemic therapy.
Agilent Technologies, 800-227-9770